Downstream use of a pour-on veterinary grade active pharmaceutical ingredient in tablets, injections, capsules, powders, granules, premixes, and pour-on solutions is governed by different particle-size, moisture, solvent, bioburden, and uniformity thresholds. The same active lot may meet a pour-on monograph but may not satisfy injectable requirements without additional bacterial endotoxin, sterility, particulate, and residual-solvent verification. Each downstream route fixes the unit-operation sequence, excipient compatibility, and release specification profile. The following scenarios are separated by manufacturing route rather than by therapeutic category.

When Direct Compression Is Applied to Low-Dose Veterinary Tablets

A direct compression route becomes feasible only when the API powder flow yields a Carr index below 25% and a Hausner ratio below 1.25 when tested according to USP <1174>. Production-scale blending in a 600 L bin blender at 60% fill volume with an intensifier bar is used for lot sizes above 200 kg; for smaller campaign sizes, a V-blender operating at 50 rpm for 15 min to 20 min is typical. A representative directly compressible frame for a 2.5% w/w active tablet may contain 68.5% w/w lactose monohydrate, 25.0% w/w microcrystalline cellulose, 3.0% w/w croscarmellose sodium, and 1.0% w/w magnesium stearate. Lubrication should not exceed 1.0% w/w because hydrophobic magnesium stearate films above 2.0% w/w are associated with extended disintegration. Compression on a rotary tablet press using 9 mm round concave tooling in the main compression force window of 8 kN to 20 kN is adjusted to achieve friability not more than 1.0% per Ph. Eur. 2.9.7. Tablet hardness commonly falls between 50 N and 100 N for a standard oral veterinary tablet, but the release specification must be confirmed against disintegration not more than 15 min in water at 37 °C per Ph. Eur. 2.9.1. Content uniformity testing follows USP <905> with acceptance value ≤15.0 for the lowest dose strength. Process drift is monitored by weight variation using in-line force sensors and periodic tablet weight sampling at 10 min intervals.

Environmental controls are maintained at 40% RH to 60% RH when the API is not strongly hygroscopic. At high-shear blending, moisture above 60% RH causes particle agglomeration and the resulting weight variability is observed on production presses as erratic fill cam depth. If the API is a hydrate or solvate, loss on drying at 105 °C per Ph. Eur. 2.2.32 should be monitored; a drying step on a fluid-bed dryer with inlet air at 50 °C to 60 °C can be applied before blending when incoming material exceeds 1.0% moisture. The terminal product is a scored oral tablet for companion animal or production animal administration, packaged in high-density polyethylene bottles with a desiccant canister where the API is moisture-labile.

Injectable manufacture from an API originally graded for pour-on use requires a documented change-over assessment covering bacterial endotoxin load, bioburden, residual solvent profile per VICH GL18, and subvisible particulate content. A terminal sterilization process at 121 °C for 15 min per Ph. Eur. 5.1.1 is preferred when the API demonstrates sufficient thermal stability in aqueous solution, typically evaluated by assay loss below 2.0% after one sterilization cycle. For heat-labile APIs, aseptic filtration through a 0.22 µm rated polyvinylidene fluoride or polyethersulfone membrane is followed by filling in an isolator or restricted access barrier system. The solvent system may include water for injection, propylene glycol, or glycofurol depending on solubility. A representative injectable solution frame may be 1.0% w/v active substance, 2.0% v/v benzyl alcohol as an antimicrobial preservative in multidose presentations, and a phosphate or citrate buffer at 10 mM to 50 mM, with sodium chloride used to adjust tonicity to 280 mOsm/kg to 320 mOsm/kg.

Particulate matter in injectables is not controlled solely by filtration; component preparation, vial washing, and depyrogenation tunnel air velocity in the range of 0.45 m/s to 0.65 m/s at 300 °C to 350 °C are common on depyrogenation tunnels, but published data for this specific API formulation is limited. Terminal products are packaged in Type I glass vials sealed with bromobutyl rubber stoppers. Filter integrity testing per ASTM F838-20 is conducted before and after filling; any post-use bubble point below the membrane manufacturer minimum requires batch quarantine and deviation review. For neonatal or rapidly growing animals, preservative concentration should be justified by toxicological data, because benzyl alcohol exposure limits are not identical across species. The operational boundary is that aseptic processing should not be used as a substitute for terminal sterilization when the API remains within assay specification after 121 °C exposure.

Wet Granulation Drying Endpoints and Binder Inputs

Wet granulation is selected when the API has a dense cohesive powder with poor flow or when low-dose content uniformity cannot be sustained by direct compression. The process begins with dry blending in a high-shear granulator of 100 L to 600 L bowl volume; a binder solution containing 3.0% w/w to 5.0% w/w povidone K30 in water is added during impeller operation at 400 rpm and chopper speed 1800 rpm. Endpoint is identified by power consumption increase of 20% to 30% above dry-mix baseline and by granulate visual consistency. Drying in a fluid-bed dryer to loss on drying not more than 2.0% to 3.0% per Ph. Eur. 2.2.32 prevents tablet picking while avoiding over-drying that increases friability. Sieve fractions between 125 µm and 1000 µm after milling are compressed; granules below 125 µm should be limited to 30% w/w to protect blend flow. A representative tablet formulation may use 5.0% w/w binder solids, 2.0% w/w crospovidone, 0.5% w/w colloidal silicon dioxide, and 0.75% w/w magnesium stearate, with lactose monohydrate and microcrystalline cellulose making up the bulk. The terminal product is an uncoated or film-coated tablet for oral dosing, with coating solution solids of 12% w/w to 15% w/w applied to 3.0% weight gain in a perforated pan coater.

If the API is sensitive to moisture, wet granulation may be replaced by slugging or dry granulation with a roller compactor at 5 MPa to 15 MPa hydraulic pressure; however, published data for this specific API configuration is limited. The decision to proceed with aqueous granulation should be supported by forced degradation data at 40 °C/75% RH over 4 weeks to detect hydrolysis or polymorphic conversion. Binder viscosity below 100 mPa·s at 20 °C is generally preferred to avoid uneven spray distribution in high-shear equipment.

Oral powders used in drenching or in-feed top-dress applications are manufactured by geometric dilution when the active fraction is below 5.0% w/w. A ribbon blender with working volume 200 L to 1000 L is charged with a carrier such as lactose monohydrate or dextrose anhydrous, followed by the active premix and then remaining diluent. Blending time is set by sampling at 8 to 10 fixed positions after 10 min, 15 min, and 20 min; acceptance is often a relative standard deviation not more than 5.0% across samples. Particle-size mismatch must be controlled because segregation increases when the API mean particle diameter differs from the carrier by more than 100 µm. Sachet filling uses auger fillers with fill weight tolerance ±5.0% for powders above 2 g and ±7.5% for smaller unit sachets depending on the pharmacopoeial weight variation requirement. The terminal product may be packed in laminated aluminium sachets with desiccant or in multi-dose plastic jars with a dosing spoon. Moisture-sensitive APIs require in-process relative humidity below 30% RH and closure desiccant.

For water-soluble oral powders intended for drench administration, the particle size should yield no residue on a 500 µm sieve after reconstitution; this is tested by visual inspection and by recording wetting time below 5 min in water at 20 °C. Cross-contamination in powder lines is controlled by segregating production bays and by performing a swab or rinse verification for active residue after line clearance.

What Limits Capsule Fill Weight Uniformity at Low Dose?

Capsule filling is constrained by the same flow thresholds as tablet direct compression but introduces a separate dosing volume fixed by capsule body size. When the API amount per capsule is below 25 mg or less than 25% of the average fill weight, content uniformity is required in addition to weight variation per USP <905> or Ph. Eur. 2.9.40. Powder bed densification in a dosator or tamping-pin capsule filler changes with fill depth and compression force; for size 3 capsules, target fill weight may be 200 mg to 250 mg, but final selection is based on tapped density and Carr index. Excipients commonly include pregelatinized starch or lactose monohydrate, with 0.5% w/w magnesium stearate. If the blend angle of repose exceeds 35°, direct capsule filling becomes erratic and a wet granulation or slugging step is introduced. Empty capsules must be conditioned at 23 °C ± 2 °C and 45% RH ± 5% RH for at least 2 h before filling to prevent gelatin embrittlement; brittle capsules cause body splitting and dusting on production lines. The terminal product is a hard capsule for oral administration, frequently used for small-animal dosage strengths where tablet splitting is undesirable.

Machine speed on an intermittent-motion capsule filler in the 10,000 capsules/h to 50,000 capsules/h range is adjusted so that fill weight relative standard deviation remains below 3.0%. Weight checks at 5 min intervals with a 50-capsule composite are used on production lines; published data for this specific formulation configuration is limited. In-process weight variation failures typically trace back to inconsistent powder bed height rather than the filling mechanism itself.

Premix Carryover Tests Require Segregated Sampling

Medicated premix production for compound feed uses a distinct regulatory pathway because the active substance is diluted into a feed carrier and later incorporated into final feed at a mill. The micro-ingredient addition sequence starts with a 1:10 dilution of the API into a carrier such as wheat middlings or ground maize with geometric mixing; this premix is then added to the main ribbon mixer at 0.5% w/w to 5.0% w/w of the final feed batch. Homogeneity acceptance in the European Union follows the medicated feed rules under Regulation (EU) 2019/4, with sample plans covering at least 10 points and active content within ±10% of the declared concentration; in FDA-regulated markets, medicated feed applications are linked to 21 CFR Part 558. Carryover validation requires segregated sampling of the first 3 to 5 batches after a medicated run, because active residues accumulate in dead zones, elevator boots, and cooler fines. Cleanout is considered effective when the following non-medicated batch has active carryover not exceeding 4% of the intended therapeutic concentration in the EU, but published data for specific APIs may require stricter producer set points. Terminal premix is packaged in 25 kg paper or woven polypropylene bags with inner polyethylene liner. Equipment-specific risk is highest in hammermill dust collection systems where fine active particles below 150 µm linger and cross-contaminate later non-medicated production.

Sampling plans should avoid composite sampling only; segregated sampling of the first discharge, mid-batch, and final discharge detects active segregation that composite samples mask. Loss-in-weight feeders and micro-dosers must be verified with calibrated check weights at the start of each campaign. The operational boundary is that high-fat carriers above 6% crude fat can bind active particles and reduce uniformity if the mixer temperature exceeds 40 °C during extended mixing.

Pour-On Solution Viscosity, Hair Coat Distribution, and Dose Metering

Topical pour-on manufacture is the closest downstream route to the original API grade but still requires solvent selection for hair coat spreading, drying time, and chemical stability. Typical solvent systems include isopropyl alcohol, propylene glycol, and dimethyl isosorbide; the choice depends on API solubility and the required deposition after a single dorsal midline application. A 0.5% w/v solution may be manufactured by dissolving the API in co-solvent at 20 °C to 30 °C in a closed stainless steel reactor, then adjusting to final volume in a solvent-recovery unit. Viscosity at 20 °C is often controlled below 100 mPa·s to allow consistent delivery from drench guns; higher viscosity can cause under-dose in 0.5 mL graduated delivery chambers. Filling in high-density polyethylene containers of 500 mL, 1 L, 2.5 L, and 5 L is followed by closure torque verification and leak testing. Dose-metering devices calibrated in 0.1 mL increments per 10 kg body weight are commonly used; published data for this specific API configuration is limited.

Hair coat distribution tests on production-scale lots typically require visual scoring of the dorsal midline at 12 h and 24 h after application to detect rapid run-off or localized pooling. Storage conditions at 25 °C/60% RH and 40 °C/75% RH follow the stability stress model in VICH GL3. Solvent evaporation during filling can raise API concentration at the end of bulk solution staging; therefore, headspace nitrogen blanketing and specific gravity checks at 30 min intervals are applied in open vessel operations. The terminal product is a ready-to-use pour-on solution for cattle or sheep, applied in a rate-controlled dose along the dorsal midline.

Formulation incompatibility with polyvinyl chloride pump tubing should be assessed when non-aqueous solvent systems are used; silicone tubing is an alternative in fixed filling lines. If the API is light-sensitive, amber high-density polyethylene containers are specified. The product remains non-sterile; application to broken skin or mucous membranes is outside the normal approval boundary unless supported by target animal safety data.